Navigation Links
Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman

LIBERTY, Mo. and DANBURY, Conn., Aug. 17, 2011 /PRNewswire/ -- Planet Biopharmaceuticals, Inc. and its wholly owned Subsidiaries (collectively, "Planet"), a privately held specialty pharmaceutical company focused on providing products for allergy and asthma sufferers, today announced that Theron (Ted) E. Odlaug, Ph.D. has been named as the company's Executive Chairman and will assume the additional role of Chief Executive Officer on August 29, 2011. Odlaug will replace William (Bill) Goldberg, who has joined MediMedia USA, Inc. as Chief Executive Officer. Goldberg will remain on Planet's board of directors as an independent director.

Odlaug will be responsible for day-to-day operations and corporate strategy. "Ted's extensive experience in the pharmaceutical and life sciences arenas make him the ideal candidate to lead the company," said Goldberg.

Scott Glenn, Chairman, commented, "Ted has an impressive record of accomplishment. We are confident in his ability to guide Planet through its next stage of corporate development. We also thank Bill for the tremendous job he has done with Planet. We wish him well in his new role with MediMedia."

"I am pleased to lead Planet at such an exciting time in the company's history," said Odlaug.

From 2008 until January of this year Ted was President and CEO of CyDex Pharmaceuticals, Inc when the company was sold under Ted's leadership to Ligand Pharmaceuticals, Inc. Prior to CyDex, Ted served as Managing Partner of EIR Healthcare Advisors, LLC. Prior to that, he was Executive Vice President and a member of the senior management committee at Fujisawa Healthcare Inc. until its merger with Yamanouchi in 2005, which resulted in the formation of Astellas Pharma. He left Astellas in 2006 after successfully supporting the U.S. post-merger integration process.

Odlaug holds Bachelor's and Master's degrees from the University of Missouri at Kansas City and a Ph.D. in Public Health from the University of Minnesota.


Planet Biopharmaceuticals, Inc.
Francesca DiNota, Vice President and CFO

SOURCE Planet Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Technology to Revolutionize the Way the Planet Does Business
2. Fountain Healthy Aging Inc Announces Agreement to Acquire Natural Planet USA
3. DNA-Planet Launches New Service for Customer-Individual Indirect DNA Paternity Testing and Kinship Analysis
4. The Biotechnology Industry Organization and Critical Path Institute Partner With Mediaplanet, Biocom, and the University of California Office to Spotlight the Science That Is Healing, Fueling and Feeding Our Global Population
5. Mediaplanet Launches Campaign for Awareness of Neurological Issues
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
7. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
9. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
10. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
Post Your Comments:
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
Breaking Biology Technology:
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):